| Assessment of HER2 status in breast cancer: why, when and how? |
| |
| 引用本文： | Dowsett M,Cooke T,Ellis I,Gullick WJ,Gusterson B,Mallon E,Walker R. Assessment of HER2 status in breast cancer: why, when and how?[J]. European journal of cancer (Oxford, England : 1990), 2000, 36(2): 170-176. DOI: 10.1016/S0959-8049(99)00264-6 |
| |
| 作者姓名： | Dowsett M Cooke T Ellis I Gullick WJ Gusterson B Mallon E Walker R |
| |
| 摘 要： |
|
| 收稿时间： | 1999-09-20 |
Assessment of HER2 status in breast cancer: why,when and how? |
| |
| Dowsett M,Cooke T,Ellis I,Gullick W J,Gusterson B,Mallon E,Walker R. Assessment of HER2 status in breast cancer: why,when and how?[J]. European journal of cancer (Oxford, England : 1990), 2000, 36(2): 170-176. DOI: 10.1016/S0959-8049(99)00264-6 |
| |
| Authors: | Dowsett M Cooke T Ellis I Gullick W J Gusterson B Mallon E Walker R |
| |
| Affiliation: | Academic Department of Biochemistry, Royal Marsden Hospital, London, UK. mitch@icr.ac.uk |
| |
| Abstract: | Human epidermal growth factor receptor 2 (HER2) is overexpressed, usually as a result of HER2 proto-oncogene amplification, in 20-30% of breast cancers. A HER2-positive status is generally associated with more aggressive disease and a worse prognosis. Furthermore, a positive HER2 status may predict the likelihood of resistance to some conventional therapies, as well as probably being predictive of sensitivity to anthracycline dose intensification. In addition to this prognostic/predictive value, HER2 is a target for specific therapy, with anti-HER2 monoclonal antibody therapy available in the USA. This article reviews the different assays used to determine HER2 status, discussing their relative advantages/disadvantages and the need for their standardisation before integration alongside other pathological indices into the clinical management of breast cancer. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
